NCT07236099 Study of the Efficacy and Safety of ICP-332 in Participants With Prurigo Nodularis
| NCT ID | NCT07236099 |
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | Beijing InnoCare Pharma Tech Co., Ltd. |
| Condition | Prurigo Nodularis (PN) |
| Study Type | INTERVENTIONAL |
| Enrollment | 135 participants |
| Start Date | 2025-11-27 |
| Primary Completion | 2027-03 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 135 participants in total. It began in 2025-11-27 with a primary completion date of 2027-03.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Evaluate the efficacy and safety of ICP-332 in participants with Prurigo Nodularis (PN)
Eligibility Criteria
Inclusion Criteria : 1. Voluntarily sign informed consent forms before any investigational procedure(s) are performed. 2. Male or female aged between 18 and 75 years at the time of signing the informed consent. 3. Clinical diagnosis of PN by a dermatologist for at least 3 months before the Screening visit. 4. At least 20 pruriginous lesions on the entire body with a bilateral distribution (on both legs, and/or both arms and/or trunk) at both screening and the baseline (Day 1) visits. 5. PP NRS score ≥ 7 at both screening and the baseline (Day 1) visits. 6. IGA-CPG-S score ≥ 3 at both the screening and the baseline (Day 1) visits. 7. History of inadequate response to topical corticosteroid of medium or higher potency or for whom topical treatments are otherwise medically inadvisable (e.g., because of important side effects or safety risks). Willingness to avoid pregnancy or fathering children Exclusion Criteria: 1. Patients with a documented AD severity moderate to severe presence of skin morbidities other than PN and mild AD that may interfere with the assessment of the study outcomes. PN secondary to medications . 2. Any uncontrolled or serious disease, or any medical, psychological, or surgical condition including relevant laboratory abnormalities at screening that may either interfere with the interpretation of the clinical trial results and/or, in the investigator's judgment, would adversely affect the patient's participation in the study. Active chronic or acute infection participant not suitable for participation, whatever the reason, as judged by the Investigator, including medical or clinical conditions, or participants potentially at risk of noncompliance to study procedures.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07236099 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Prurigo Nodularis (PN). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07236099 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT07236099 currently recruiting?
Yes, NCT07236099 is actively recruiting participants. Contact the research team at CO_HGRAC@innocarepharma.com for enrollment information.
Where is the NCT07236099 trial being conducted?
This trial is being conducted at Mayfield Heights, United States, Wuhu, China, Beijing, China, Chongqing, China and 11 additional locations.
Who is sponsoring the NCT07236099 clinical trial?
NCT07236099 is sponsored by Beijing InnoCare Pharma Tech Co., Ltd.. The trial plans to enroll 135 participants.